Literature DB >> 31757421

TOPK promotes epithelial-mesenchymal transition and invasion of breast cancer cells through upregulation of TBX3 in TGF-β1/Smad signaling.

Young-Ju Lee1, Jung-Hwan Park1, Sang-Muk Oh2.   

Abstract

TOPK has been suggested to contribute to invasion of lung, prostate, gastric, pancreatic or breast cancer cells. However, how TOPK mediates TGF-β1/Smad signaling leading to epithelial-mesenchymal transition (EMT) and invasion of breast cancer cells remains unknown. Here we report that TOPK upregulates T-box transcription factor TBX3 to enhance TGF-β1-induced EMT and invasion of MDA-MB-231 breast cancer cells. Expression of endogenous TOPK was promoted by TGF-β1 treatment of MDA-MB-231 cells time-dependently. In addition, knockdown of TOPK attenuated TGF-β1-induced phosphorylation or transcriptional activity of Smad3. Meanwhile, levels of both mRNA and protein of TBX3 induced by TGF-β1 were abolished by TOPK depletion. Also, knockdown of TBX3 inhibited TGF-β1 induction of EMT-related genes Snail, Slug or Fibronectin. Furthermore, ablation of TOPK or TBX3 suppressed TGF-β1-induced MDA-MB-231 cell invasion. Collectively, we conclude that TOPK positively regulates TBX3 in TGF-β1/Smad signaling pathway, thereby enhancing EMT and invasion of breast cancer cells, implying a mechanistic role of TOPK in TGF-β1/Smad signaling.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Breast cancer; Epithelial-mesenchymal transition; Invasion; TBX3; TGF-β1; TOPK

Mesh:

Substances:

Year:  2019        PMID: 31757421     DOI: 10.1016/j.bbrc.2019.11.104

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

Review 1.  The role of T-LAK cell-originated protein kinase in targeted cancer therapy.

Authors:  Lu Zhang; Fei Wang; Huijun Yi; Svetlana P Ermakova; Olesya S Malyarenko; Jianmei Mo; Yingze Huang; Qiuhong Duan; Juanjuan Xiao; Feng Zhu
Journal:  Mol Cell Biochem       Date:  2022-01-17       Impact factor: 3.396

Review 2.  The Role of Noncoding RNAs in the Regulation of Anoikis and Anchorage-Independent Growth in Cancer.

Authors:  Han Yeoung Lee; Seung Wan Son; Sokviseth Moeng; Soo Young Choi; Jong Kook Park
Journal:  Int J Mol Sci       Date:  2021-01-10       Impact factor: 5.923

3.  3-Deoxysappanchalcone Inhibits Skin Cancer Proliferation by Regulating T-Lymphokine-Activated Killer Cell-Originated Protein Kinase in vitro and in vivo.

Authors:  Xiaorong Fu; Ran Zhao; Goo Yoon; Jung-Hyun Shim; Bu Young Choi; Fanxiang Yin; Beibei Xu; Kyle Vaughn Laster; Kangdong Liu; Zigang Dong; Mee-Hyun Lee
Journal:  Front Cell Dev Biol       Date:  2021-03-25

4.  PBK/TOPK Inhibitor Suppresses the Progression of Prolactinomas.

Authors:  Kejing Zhu; Xueting Cheng; Shuman Wang; Hong Zhang; Yu Zhang; Xiong Wang; Yonggang Chen; Jinhu Wu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-21       Impact factor: 5.555

Review 5.  PBK/TOPK: An Effective Drug Target with Diverse Therapeutic Potential.

Authors:  Hai Huang; Mee-Hyun Lee; Kangdong Liu; Zigang Dong; Zeayoung Ryoo; Myoung Ok Kim
Journal:  Cancers (Basel)       Date:  2021-05-06       Impact factor: 6.639

Review 6.  Polyphenols Modulating Effects of PD-L1/PD-1 Checkpoint and EMT-Mediated PD-L1 Overexpression in Breast Cancer.

Authors:  Samia S Messeha; Najla O Zarmouh; Karam F A Soliman
Journal:  Nutrients       Date:  2021-05-19       Impact factor: 5.717

7.  Plac8-mediated autophagy regulates nasopharyngeal carcinoma cell function via AKT/mTOR pathway.

Authors:  Mao-Ling Huang; Cheng-Lin Qi; You Zou; Rui Yang; Yang Jiang; Jian-Fei Sheng; Yong-Gang Kong; Ze-Zhang Tao; Shi-Ming Chen
Journal:  J Cell Mol Med       Date:  2020-05-29       Impact factor: 5.310

8.  T-LAK cell-originated protein kinase (TOPK): an emerging prognostic biomarker and therapeutic target in osteosarcoma.

Authors:  Pichaya Thanindratarn; Ran Wei; Dylan C Dean; Arun Singh; Noah Federman; Scott D Nelson; Francis J Hornicek; Zhenfeng Duan
Journal:  Mol Oncol       Date:  2021-06-29       Impact factor: 6.603

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.